Do analysts prefer GRML or CVKD?

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Greenland Mines Ltd. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, GRML or CVKD?

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is GRML or CVKD more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Cadrenal Therapeutics N/A -411.03% -275.61%

Do analysts rate ADXS or CVKD?

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ADXS or CVKD more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media favor ALGS or CVKD?

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Aligos Therapeutics. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat Cadrenal Therapeutics' score of -0.03 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CVKD or ABVC?

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CVKD or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -411.03% -275.61% ABVC BioPharma N/A -62.46% -39.99%

Does the media prefer CVKD or ABVC?

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Cadrenal Therapeutics' score of -0.03 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ZYBT or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, ZYBT or CVKD?

Zhengye Biotechnology has higher revenue and earnings than Cadrenal Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 2.03 -$9.98M N/A N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is ZYBT or CVKD more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Cadrenal Therapeutics N/A -411.03% -275.61%

Cadrenal Therapeutics (CVKD) Competitors

$3.05 +0.19 (+6.64%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$3.06 +0.01 (+0.16%)

As of 06/26/2026 04:10 PM Eastern

Compare

CVKD vs. GRML, ADXS, ALGS, ABVC, and ZYBT

Should you buy Cadrenal Therapeutics stock or one of its competitors? MarketBeat compares Cadrenal Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadrenal Therapeutics include Greenland Mines Ltd. Common Stock (GRML), Ayala Pharmaceuticals (ADXS), Aligos Therapeutics (ALGS), ABVC BioPharma (ABVC), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Cadrenal Therapeutics compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Greenland Mines Ltd. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 8 mentions for Greenland Mines Ltd. Common Stock. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.13 beat Cadrenal Therapeutics' score of -0.03 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Greenland Mines Ltd. Common Stock has a beta of 6.94, suggesting that its stock price is 594% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Summary

Greenland Mines Ltd. Common Stock beats Cadrenal Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Cadrenal Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 10 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.03 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Cadrenal Therapeutics	Neutral

Ayala Pharmaceuticals' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ayala Pharmaceuticals and Cadrenal Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Cadrenal Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.74	-$24.19M	-$8.69	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Aligos Therapeutics. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat Cadrenal Therapeutics' score of -0.03 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadrenal Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadrenal Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Aligos Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 591.20%. Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 326.23%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats Cadrenal Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to ABVC BioPharma?

Cadrenal Therapeutics (NASDAQ:CVKD) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

ABVC BioPharma's return on equity of -62.46% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
ABVC BioPharma	N/A	-62.46%	-39.99%

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than Cadrenal Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
ABVC BioPharma	$510K	77.44	-$7.91M	-$0.40	N/A

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cadrenal Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Cadrenal Therapeutics' score of -0.03 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cadrenal Therapeutics and ABVC BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Zhengye Biotechnology has higher revenue and earnings than Cadrenal Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.03	-$9.98M	N/A	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 326.23%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 10 mentions for Cadrenal Therapeutics and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.43 beat Cadrenal Therapeutics' score of -0.03 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Cadrenal Therapeutics	Neutral

Zhengye Biotechnology has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zhengye Biotechnology's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Summary

Cadrenal Therapeutics beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.20M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-0.54	21.56	25.84	24.18
Price / Sales	N/A	334.99	576.85	114.69
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	2.61	8.34	10.78	6.36
Net Income	-$13.24M	$23.91M	$3.58B	$337.99M
7 Day Performance	-12.86%	3.42%	2.22%	0.10%
1 Month Performance	-38.01%	1.55%	1.11%	-0.11%
1 Year Performance	-70.79%	65.22%	34.28%	27.60%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.6549 of 5 stars	$3.05 +6.6%	$13.00 +326.2%	-70.3%	$8.75M	N/A	N/A	4	Gap Down
GRML Greenland Mines Ltd. Common Stock	0.9046 of 5 stars	$0.26 -13.8%	N/A	-77.4%	$36.01M	N/A	N/A	5	News Coverage Gap Down
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
ALGS Aligos Therapeutics	3.0666 of 5 stars	$5.65 -0.7%	$38.50 +581.4%	-22.0%	$35.21M	$2.19M	N/A	90	News Coverage Analyst Downgrade Gap Down
ABVC ABVC BioPharma	0.7173 of 5 stars	$1.31 -0.8%	N/A	-30.6%	$34.32M	$510K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. GRML, ADXS, ALGS, ABVC, and ZYBT

How does Cadrenal Therapeutics compare to Greenland Mines Ltd. Common Stock?

Summary

How does Cadrenal Therapeutics compare to Ayala Pharmaceuticals?

Summary

How does Cadrenal Therapeutics compare to Aligos Therapeutics?

Summary

How does Cadrenal Therapeutics compare to ABVC BioPharma?

Summary

How does Cadrenal Therapeutics compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. GRML, ADXS, ALGS, ABVC, and ZYBT

How does Cadrenal Therapeutics compare to Greenland Mines Ltd. Common Stock?

Do analysts prefer GRML or CVKD?

Which has stronger valuation & earnings, GRML or CVKD?

Do institutionals and insiders have more ownership in GRML or CVKD?

Does the media favor GRML or CVKD?

Which has more risk and volatility, GRML or CVKD?

Is GRML or CVKD more profitable?

Summary

How does Cadrenal Therapeutics compare to Ayala Pharmaceuticals?

Do institutionals & insiders have more ownership in ADXS or CVKD?

Which has more volatility & risk, ADXS or CVKD?

Which has better valuation and earnings, ADXS or CVKD?

Does the media favor ADXS or CVKD?

Is ADXS or CVKD more profitable?

Do analysts rate ADXS or CVKD?

Summary

How does Cadrenal Therapeutics compare to Aligos Therapeutics?

Which has higher earnings & valuation, ALGS or CVKD?

Does the media favor ALGS or CVKD?

Is ALGS or CVKD more profitable?

Which has more volatility and risk, ALGS or CVKD?

Do analysts recommend ALGS or CVKD?

Do insiders & institutionals have more ownership in ALGS or CVKD?

Summary

How does Cadrenal Therapeutics compare to ABVC BioPharma?

Is CVKD or ABVC more profitable?

Do analysts recommend CVKD or ABVC?

Which has better earnings and valuation, CVKD or ABVC?

Do institutionals and insiders have more ownership in CVKD or ABVC?

Which has more risk & volatility, CVKD or ABVC?

Does the media prefer CVKD or ABVC?

Summary

How does Cadrenal Therapeutics compare to Zhengye Biotechnology?

Which has higher valuation and earnings, ZYBT or CVKD?

Do analysts recommend ZYBT or CVKD?

Does the media prefer ZYBT or CVKD?

Which has more volatility & risk, ZYBT or CVKD?

Do institutionals & insiders have more ownership in ZYBT or CVKD?

Is ZYBT or CVKD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools